Information de reference pour ce titreAccession Number: | 00005792-201709080-00049.
|
Author: | Huang, Ya MD; Heng, Chunni RN; Wei, Jing MD; Jing, Xiaorui MD; Wang, Xiaoguang MD; Zhao, Guohong MD; Hou, Junfeng MD, PhD; Liu, Qingquan MD, PhD; Jiao, Kai MD, PhD *
|
Institution: | Department of Endocrinology, Tang-Du Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
|
Title: | Influencing factors of glycemic variability in hospitalized type 2 diabetes patients with insulin therapy: A Strobe-compliant article.[Article]
|
Source: | Medicine. 96(36):e8021, September 2017.
|
Abstract: | Previous studies have shown that glucose fluctuation is closely related to oxidative stress and diabetic complications. However, only few studies have evaluated the influencing factors of glycemic variability (GV) in type 2 diabetes (T2D) patients so far.
This was a cross-sectional study design. A total of 366 cases of hospitalized patients with T2D using insulin therapy, whom received continuous glucose monitoring from January 2014 to December 2016, were enrolled for this study. The evaluation variables of GV included standard deviation of blood glucose, coefficient of variation (CV%), mean amplitude of glycemic excursion, and absolute means of daily differences.
In 366 T2D patients with insulin therapy, 148 were used multiple daily injections (MDI) insulin regimen; 144 were on premixed insulin injection; and 74 were treated with continuous subcutaneous insulin injection. Compared with MDI insulin regimen, patients on premixed insulin injection have less insulin dose per day, lower mean blood glucose, and better glycated hemoglobin (HbA1c) (all P <.05). Generalized linear model showed that family history of diabetes, duration of diabetes, higher HbA1c, and higher level of aspartate aminotransferase and high-density lipoprotein cholesterol were positively associated with GV parameters. Otherwise, serum levels of C-peptide, premixed insulin injection, history of cardiovascular disease, and serum concentration of uric acid were inversely associated with GV parameters.
Dysfunction of pancreatic [beta]-cell and better insulin sensitivity were independent contributors to the fluctuation of blood glucose. Moreover, premixed insulin therapy may obtain better glucose control and lower within-day and day-to-day glucose variability for Chinese T2D patients with insulin therapy.
Copyright (C) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.
|
Author Keywords: | C-peptide; glycemic variability; influencing factors; type 2 diabetes.
|
References: | [1]. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
[2]. O'Sullivan EP, Dinneen SF. Benefits of early intensive glucose control to prevent diabetes complications were sustained for up to 10 years. Evid Based Med 2009;14:9-10.
[3]. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54:1-7.
[4]. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-7.
[5]. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707-8.
[6]. Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers!. Diabetes Care 2015;38:1615-21.
[7]. Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 2002;51(suppl 1):S109-16.
[8]. Service FJ, Nelson RL. Characteristics of glycemic stability. Diabetes Care 1980;3:58-62.
[9]. Kohnert KD, Augstein P, Zander E, et al. Glycemic variability correlates strongly with postprandial-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 2009;32:1058-62.
[10]. Jin S-M, Kim T-H, Bae JC, et al. Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: An analysis of 480 subjects. Diabetes Res Clin Pract 2014;104:266-72.
[11]. Service FJ. Glucose variability. Diabetes 2013;62:1398-404.
[12]. DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes 2013;62:1405-8.
[13]. Service FJ, Molnar GD, Rosevear JW, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19:644-55.
[14]. Greven WL, Beulens JW, Biesma DH, et al. Glycemic variability in inadequately controlled type 1 diabetes and type 2 diabetes on intensive insulin therapy: a cross-sectional, observational study. Diabetes Technol Ther 2010;12:695-9.
[15]. Murata GH, Duckworth WC, Shah JH, et al. Sources of glucose variability in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Clin Endocrinol (Oxf) 2004;60:451-6.
[16]. Gjesing AP, Pedersen O. 'Omics'-driven discoveries in prevention and treatment of type 2 diabetes. Eur J Clin Invest 2012;42:579-88.
[17]. Xu M, Huang Y, Xie L, et al. Diabetes and risk of arterial stiffness: a Mendelian randomization analysis. Diabetes 2016;65:1731-40.
[18]. Garber AJ, Ligthelm R, Christiansen JS, et al. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007;9:630-9.
[19]. Bellido V, Suarez L, Rodriguez MG, et al. Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes. Diabetes Care 2015;38:2211-6.
[20]. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-101.
[21]. International Diabetes Federation Guideline Development Group. Guideline for management of postmeal glucose in diabetes. Diabetes Res Clin Pract 2014;103:256-68.
[22]. Chen J, Wildman RP, Hamm LL, et al. Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2960-5.
[23]. Avula NR, Shenoy D. Evaluation of association of hyperuricaemia with metabolic syndrome and insulin resistance. J Clin Diagn Res 2016;10:OC32-4.
[24]. Zhang Y, Lee ET, Howard BV, et al. Insulin resistance, incident cardiovascular diseases, and decreased kidney function among nondiabetic American Indians: the Strong Heart Study. Diabetes Care 2013;36:3195-200.
[25]. Hayashibe H, Asayama K, Nakane T, et al. Decreased activity of plasma cholesteryl ester transfer protein in children and adolescents with insulin-dependent diabetes mellitus. Acta Paediatr 1999;88:1067-70.
|
Language: | English.
|
Document Type: | Research Article: Observational Study.
|
Journal Subset: | Nursing. Clinical Medicine. Health Professions. Pharmacology.
|
ISSN: | 0025-7974
|
NLM Journal Code: | mny, 2985248r
|
DOI Number: | https://dx.doi.org/10.1097/MD.00...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|